» Articles » PMID: 15016844

Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8+ T Cells: Correlation with Viral Load

Abstract

An understanding of the relationship between the breadth and magnitude of T-cell epitope responses and viral loads is important for the design of effective vaccines. For this study, we screened a cohort of 46 subtype C human immunodeficiency virus type 1 (HIV-1)-infected individuals for T-cell responses against a panel of peptides corresponding to the complete subtype C genome. We used a gamma interferon ELISPOT assay to explore the hypothesis that patterns of T-cell responses across the expressed HIV-1 genome correlate with viral control. The estimated median time from seroconversion to response for the cohort was 13 months, and the order of cumulative T-cell responses against HIV proteins was as follows: Nef > Gag > Pol > Env > Vif > Rev > Vpr > Tat > Vpu. Nef was the most intensely targeted protein, with 97.5% of the epitopes being clustered within 119 amino acids, constituting almost one-third of the responses across the expressed genome. The second most targeted region was p24, comprising 17% of the responses. There was no correlation between viral load and the breadth of responses, but there was a weak positive correlation (r = 0.297; P = 0.034) between viral load and the total magnitude of responses, implying that the magnitude of T-cell recognition did not contribute to viral control. When hierarchical patterns of recognition were correlated with the viral load, preferential targeting of Gag was significantly (r = 0.445; P = 0.0025) associated with viral control. These data suggest that preferential targeting of Gag epitopes, rather than the breadth or magnitude of the response across the genome, may be an important marker of immune efficacy. These data have significance for the design of vaccines and for interpretation of vaccine-induced responses.

Citing Articles

Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119.

Kalams S, Felber B, Mullins J, Scott H, Allen M, De Rosa S JCI Insight. 2024; 9(18).

PMID: 39088271 PMC: 11466283. DOI: 10.1172/jci.insight.180819.


Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.

Nelson G, van Duijn J, Yuki Y, Pau M, Tomaka F, Lavreys L J Virol. 2024; 98(8):e0028124.

PMID: 39046263 PMC: 11338073. DOI: 10.1128/jvi.00281-24.


Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention.

Tarres-Freixas F, Clotet B, Carrillo J, Blanco J Vaccines (Basel). 2024; 12(3).

PMID: 38543932 PMC: 10975260. DOI: 10.3390/vaccines12030298.


A longitudinal analysis of immune escapes from HLA-B*13-restricted T-cell responses at early stage of CRF01_AE subtype HIV-1 infection and implications for vaccine design.

Zhang H, He C, Jiang F, Cao S, Zhao B, Ding H BMC Immunol. 2022; 23(1):15.

PMID: 35366796 PMC: 8976269. DOI: 10.1186/s12865-022-00491-7.


Deep sequencing of the HIV-1 polymerase gene for characterisation of cytotoxic T-lymphocyte epitopes during early and chronic disease stages.

Nkone P, Loubser S, Quinn T, Redd A, Ismail A, Tiemessen C Virol J. 2022; 19(1):56.

PMID: 35346259 PMC: 8959563. DOI: 10.1186/s12985-022-01772-8.


References
1.
Altfeld M, Addo M, Shankarappa R, Lee P, Allen T, Yu X . Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol. 2003; 77(13):7330-40. PMC: 164796. DOI: 10.1128/jvi.77.13.7330-7340.2003. View

2.
Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath M . Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol. 2003; 77(12):6867-78. PMC: 156203. DOI: 10.1128/jvi.77.12.6867-6878.2003. View

3.
Koup R, Safrit J, Cao Y, Andrews C, McLeod G, Borkowsky W . Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994; 68(7):4650-5. PMC: 236393. DOI: 10.1128/JVI.68.7.4650-4655.1994. View

4.
Klein M, van Baalen C, Holwerda A, Kerkhof Garde S, Bende R, Keet I . Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 1995; 181(4):1365-72. PMC: 2191947. DOI: 10.1084/jem.181.4.1365. View

5.
Rinaldo C, Huang X, Fan Z, Ding M, BELTZ L, Logar A . High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol. 1995; 69(9):5838-42. PMC: 189455. DOI: 10.1128/JVI.69.9.5838-5842.1995. View